ABSTRACT
Pulmonary rehabilitation (PR) provides those with chronic lung disease the opportunity to improve their exercise capacity and quality of life. Physiological limitations associated with the underlying lung disease impact an individual's potential training capability. This chapter provides an overview of the supplementary pharmacological therapies that have been previously shown to provide additional benefit to pulmonary rehabilitation. In addition to the role of bronchodilators, we also comment on recent innovative trials that target both the lung and the peripheral muscle. Whereas some therapies provide clear benefit, others remain experimental.
